摘要
目的:观察贝伐单抗联合Xelox方案(奥沙利铂^(+)卡培他滨)在局部晚期结肠癌患者治疗中的应用效果。方法:选取2021年1月—2023年5月临沂市中心医院肿瘤科收治的局部晚期结肠癌患者中60例,采用随机数字表法分为对照组与观察组各30例。对照组患者静脉滴注奥沙利铂,并口服卡培他滨片治疗;观察组患者在对照组治疗的基础上口服贝伐珠单抗治疗。比较两组临床疗效、血清免疫指标、血清肿瘤标志物水平及不良反应。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组CD4^(+)及CD4^(+)/CD8^(+)水平均高于治疗前,且观察组CD4^(+)及CD4^(+)/CD8^(+)水平均高于对照组,差异有统计学意义(P<0.05);两组血清癌胚抗原(CEA)及糖类抗原199(CA199)水平低于治疗前,且观察组CEA、CA199水平均低于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:贝伐单抗联合Xelox方案可有效提升局部晚期结肠癌患者的临床疗效,改善患者的血清免疫指标,调节血清肿瘤标志物,且安全性较好。
Objective To observe the effect of bevacizumab combined with Xelox(oxaliplatin^(+)capecitabine)in the treatment of locally advanced colon cancer patients.Methods A total of 60 patients with locally advanced colon cancer admitted to Oncology Department of Linyi Central Hospital from January 2021 to May 2023 were selected and divided into control group and observation group with 30 cases in each group by random number table method.The control group was given oxaliplatin intravenously and capecitabine tablets orally,the observation group was treated with oral bevacizumab based on control group.The clinical efficacy,serum immune indexes,serum tumor markers and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of CD4^(+) and CD4^(+)/CD8^(+) in 2 groups were higher than before treatment,and the levels of CD4^(+) and CD4^(+)/CD8^(+) in observation group were higher than those in control group,with statistical significance(P<0.05).The levels of carcinoembryonic antigen(CEA)and carbohydrate antigen 199(CA199)in 2 groups were lower than before treatment,and the CEA and CA199 levels in observation group were lower than those in control group,the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusions Bevacizumab combined with Xelox regimen can effectively improve the clinical efficacy of patients with locally advanced colon cancer,improve the serum immune indexes of patients,regulate serum tumor markers,and have good safety.
作者
王明霞
WANG Mingxia(Department of Oncology,Linyi Central Hospital,Linyi,Shandong 276400,China)
出处
《医药前沿》
2024年第11期4-7,共4页
Journal of Frontiers of Medicine
